摘要
目的系统分析康莱特联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌的有效性。方法计算机检索Pub Med、EMbase数据库、中国科技期刊全文数据库、万方数据库,纳入符合入选标准的文献进行统计分析。结果共纳入4篇文献,结果显示康莱特+GP组与单纯GP化疗组治疗有效率无明显差异(RR=1.21,95%CI 0.9~1.62);康莱特+GP组生活质量明显提高(RR=1.58,95%CI 1.28~1.96)。结论康莱特联合GP方案化疗不影响晚期非小细胞肺癌患者治疗有效率,但可明显改善其生活质量。
Objective A meta-analysis of published studies was conducted in the present study,aims to estimate the validity of Kanglaite combined GP scheme in treatment non-small cell lung cancer( NSCLC). Methods CJFD and Wan Fang database was searched up to January,2015 to identify eligible studies. Pooled relative risk( RR) estimates and 95% confidence intervals( CIs) were calculated. Results Effective rate of Kanglaite + GP was equal to GP in treating NSCLC.( RR = 1. 21,95% CI 0. 9-1. 62). Life quality improved significantly in Kanglaite + GP group( RR = 1. 58,95% CI 1. 28-1. 96). Low publication bias was observed. Conclusion Kanglaite significantly improved life quality of NSCLC patients,and more research is needed to confirm this finding.
出处
《延安大学学报(医学科学版)》
2016年第2期20-22,共3页
Journal of Yan'an University:Medical Science Edition
关键词
康莱特
吉西他滨
顺铂
非小细胞肺癌
Kanglaite
Gemcitabine
Cisplatin
Non-small cell lung cancer